Synbiotic composition and application thereof

Abstract

The invention discloses a synbiotics composition and application thereof, and relates to the technical field of functional food. The synbiotic composition disclosed by the invention is prepared from probiotics and prebiotics, the probiotics are selected from at least one of lactobacillus acidophilus NCFM and lactobacillus plantarum 6595; the prebiotics are selected from at least one of stachyose, fructo-oligosaccharide and yeast spore beta-glucan. According to the invention, the hypoglycemic ability, lipid-lowering ability, gastrointestinal tract tolerance, Caco-2 cell adhesion ability, antagonism among strains and the like of the three kinds of bacterial powder are researched in an in-vitro culture mode, and it is determined that lactobacillus acidophilus and lactobacillus plantarum can have synergistic interaction after being compounded. Meanwhile, optimal prebiotics capable of promoting bacterial strain proliferation are screened out for compounding, the influence of the prebiotics compounded in different proportions on mixed bacterial strain proliferation is measured, and the optimal compounding proportion of the prebiotics is determined in combination with an in-vitro simulated colon fermentation experiment, so that a theoretical basis is provided for development of an optimal formula of probiotics-prebiotics (synbiotics).

Description

Technical Field

[0001] The present invention relates to the technical field of functional foods, and in particular to a synbiotic composition and application thereof. Background Art

[0002] Diabetes and cardiovascular disease are among the leading causes of death and disease worldwide. Although there are currently a variety of glucose-lowering and lipid-lowering drugs that can effectively control blood sugar and lipid levels, long-term use of drugs is often accompanied by side effects, such as liver and kidney damage. In addition, patient compliance is poor, especially when faced with complex drug treatment regimens. Therefore, there is an urgent need for an alternative that is safer, has fewer side effects, and can effectively manage blood sugar and lipids in the long term.

[0003] Synbiotics is a combination of probiotics and prebiotics. Probiotics help regulate metabolic functions by improving the balance of intestinal flora; while prebiotics can selectively promote the metabolism and proliferation of beneficial bacteria in the body, which can help improve the health of the body. Chinese patent CN110150669A discloses a probiotic composition suitable for diabetic patients and its application. The composition of the provided probiotic composition includes Lactobacillus plantarum YMC1005 (commercial number LP45), Lactobacillus acidophilus La28, Bifidobacterium lactis BAL531, and prebiotics. The probiotic composition can be used as a functional food for patients with type 2 diabetes and can improve the blood sugar status of patients with type 2 diabetes. Chinese patent CN117243376A discloses a synbiotic microecological preparation and its application with the function of improving metabolic syndrome, the components include probiotics and prebiotics; the probiotics include animal Bifidobacterium lactis subspecies WHH2276, Lactobacillus fermentum WHH3906, Lactobacillus fermentum 2644 and Lactobacillus rhamnosus 1155; the prebiotics include oligofructose and oligogalactose. Most of the existing studies have focused on the effects of probiotics or prebiotics alone on metabolic health, but there are relatively few studies on synbiotic combinations in terms of lowering blood sugar and lipids, and factors such as the type and proportion of the combination are still being explored. This provides huge potential for the development of new synbiotic combinations, and its role in regulating metabolism can be further enhanced by optimizing the combination.

[0004] In view of this, in order to solve the deficiencies of the prior art, the present invention provides a synbiotic composition and application thereof. Summary of the invention

[0005] The purpose of the present invention is to provide a synbiotic composition and its application, which greatly improves the in vitro blood sugar-lowering ability, in vitro cholesterol-lowering ability and intestinal flora proliferation ability of the synbiotic composition.

[0006] To achieve the above-mentioned purpose of the invention, the technical solution of the present invention is as follows:

[0007] In one aspect, the present invention provides a synbiotic composition, the synbiotic composition comprising probiotics and prebiotics;

[0008] The probiotics are selected from at least one of Lactobacillus acidophilus NCFM and Lactobacillus plantarum 6595;

[0009] The prebiotic is selected from at least one of stachyose, oligofructose and yeast spore β-glucan.

[0010] Preferably, the probiotics are Lactobacillus acidophilus NCFM and Lactobacillus plantarum 6595.

[0011] Further preferably, the mass ratio of Lactobacillus acidophilus NCFM to Lactobacillus plantarum 6595 is 1:0.1-1.

[0012] More preferably, the mass ratio of Lactobacillus acidophilus NCFM to Lactobacillus plantarum 6595 is 1:1.

[0013] Preferably, the prebiotics are stachyose, oligofructose and yeast spore β-glucan.

[0014] Further preferably, the mass ratio of stachyose, oligofructose and yeast spore β-glucan is 1-3:1-3:1-3.

[0015] More preferably, the mass ratio of stachyose, oligofructose and water-soluble β-glucan is 2-3:2-3:1.

[0016] More preferably, the mass ratio of stachyose, oligofructose and water-soluble β-glucan is 3:2:1.

[0017] Preferably, the mass ratio of the probiotics to the prebiotics is 1:0.1-1.

[0018] Further preferably, the mass ratio of the probiotics to the prebiotics is 1:1.

[0019] In another aspect, the present invention provides use of the synbiotic composition in preparing food, dietary supplement or medicine.

[0020] Preferably, the food, dietary supplement or medicament is used to treat one or more of the following diseases and conditions in a mammal:

[0021] (1) Regulate intestinal flora;

[0022] (2) Improve blood sugar and blood lipid abnormalities;

[0023] (3) improving obesity, reducing body fat mass, and / or reducing mesenteric fat mass;

[0024] (4) Improve type 2 diabetes;

[0025] (5) Improve insulin resistance.

[0026] The beneficial effects of the present invention are:

[0027] (1) The synbiotics provided by the present invention are a combination of multiple probiotics and multiple prebiotics, which can interact synergistically in the complex intestinal environment and can better improve metabolic syndrome.

[0028] (2) The present invention provides a synbiotic composition and its application. The hypoglycemic ability, lipid-lowering ability, gastrointestinal tolerance, Caco-2 cell adhesion ability, antagonism between strains, etc. of three kinds of bacterial powder (Lactobacillus acidophilus, Lactobacillus plantarum and their mixed bacteria) are studied by in vitro culture, and it is determined that Lactobacillus acidophilus and Lactobacillus plantarum can synergistically enhance the effect after being compounded.

[0029] (3) The present invention studies the effects of different types of prebiotics on the growth of three kinds of bacterial powders and determines that stachyose, oligofructose, and yeast spore β-glucan are most conducive to the growth of the three kinds of bacterial powders.

[0030] (4) The present invention studies the effects of different compound ratios of prebiotics (stachyose, oligofructose, yeast spore β-glucan) on the proliferation of mixed strains, and combines colon fermentation experiments to determine that the optimal compound ratio of prebiotics is 3:2:1.

[0031] (5) The synbiotic composition provided by the present invention has a good ability to regulate intestinal flora. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 The growth of Lactobacillus plantarum in different types of prebiotics.

[0033] Figure 2 The growth of mixed strains in different types of prebiotics.

[0034] Figure 3 The growth of Lactobacillus acidophilus in different types of prebiotics.

[0035] Figure 4 The utilization of different prebiotics by the three strains.

[0036] Figure 5 The growth of mixed strains in prebiotics with different compound ratios.

[0037] Figure 6 The results of colon fermentation experiments of prebiotics with different compound ratios, where LAC / UNI represents Lactobacillus regulation, BIF / UNI represents Bifidobacterium regulation, and AKK / UNI represents Akkermansia regulation; different lowercase letters in the figure indicate significant differences.

[0038] Figure 7 The growth and acid production of Lactobacillus plantarum, Lactobacillus acidophilus and mixed strains in the optimal compound ratio of prebiotics. DETAILED DESCRIPTION

[0039] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is only an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the invention of the present invention based on the disclosed content, and they should also fall within the scope of the present invention.

[0040] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the contents described below are all weight contents. Unless otherwise specified, it is understood that the process is carried out at room temperature.

[0041] 1. Reagents

[0042] Lactobacillus acidophilus NCFM freeze-dried powder was purchased from Danisco (China) Co., Ltd.

[0043] Lactobacillus plantarum 6595 freeze-dried powder was purchased from Danisco (China) Co., Ltd.

[0044] The mixed strains (Lactobacillus acidophilus NCFM and Lactobacillus plantarum 6595) were mixed in a mass ratio (m / m) of 1:1.

[0045] 2. Preparation of reagents

[0046] (1) Cholesterol (0.1 mg / mL)-MRS medium: Weigh (m / m) bile salts, sucrose, cholesterol, and fatty acid esters in a ratio of 2:1:1, add 1 part of Tween-80 and 5 parts of anhydrous ethanol, mix well, sonicate in an 80°C water bath until completely dissolved, and add to MRS medium and mix well.

[0047] (2) Fermentation medium (1 L): 0.1 g sodium chloride, 0.04 g dipotassium hydrogen phosphate, 0.04 g potassium dihydrogen phosphate, 0.01 g magnesium sulfate, 0.01 g calcium chloride, 2 g sodium bicarbonate, 2.5 g peptone, 4 g yeast extract, 0.4 g glucose, 2 g mucin, 0.5 g No. III bile salt, 0.46 g cysteine ​​hydrochloride, 2 mL Tween-80. Mix and adjust to pH 7.0 (1 M HCl), sterilize by high pressure wet heat at 121°C for 15 min, and set aside after cooling.

[0048] (3) Simulated gastric fluid: Weigh 0.35 g of pepsin (250 U / mg) into 100 mL of 0.2% sterile saline, adjust the pH to 3.0 with 1 M HCl, and filter and sterilize to obtain simulated gastric fluid.

[0049] (4) Simulated intestinal fluid: Weigh 0.1 g pancreatic enzyme (4 U), 0.3 g No. III bile salt and 1.1 g NaHCO3, dissolve in 100 mL 0.2% sterile saline, adjust the pH to 8.0, and filter through a sterile filter membrane.

[0050] 3. Bacterial activation and sample preparation

[0051] Weigh 0.1 g of bacterial powder into 5 mL of MRS broth and cultivate in an anaerobic incubator at 37°C. Subculture once every 12 hours (take 200 μL of the mother solution and add it to the new broth medium). Take the strain in the logarithmic growth phase, centrifuge at 8000 rpm / min for 1 min, discard the supernatant in a clean bench, add a certain amount of sterile PBS to the bacterial sludge sediment, and adjust the bacterial suspension concentration to OD 600 = 1, vortex to mix, and set aside.

[0052] Example 1 Screening of strains

[0053] 1. Gastrointestinal tolerance analysis

[0054] 1.1 Analysis Method

[0055] Take 0.5mL of the test bacterial solution and inoculate it into 4.5mL of gastric fluid, shake and culture it at 37℃ for 1.5h, and take samples at 0h and 1.5h respectively; take 0.5mL of the sample digested for 1.5h in the stomach and inoculate it into 4.5mL of simulated intestinal fluid, shake and culture it at 37℃ for 3h, and use the plate count method to detect the number of viable bacteria. Calculation formula: initial colony count / colony count after digestion in simulated gastric fluid or simulated intestinal fluid.

[0056] 1.2 Analysis Results

[0057] The survival of the strains in the simulated gastrointestinal environment is shown in Table 1. The survival rates of the three bacterial powders in simulated gastric juice are all above 90%, among which Lactobacillus plantarum has the highest survival rate of 105.21% in simulated gastric juice, that is, it can completely tolerate the gastric acid environment and has a certain proliferation ability in simulated gastric juice. The highest survival rate in simulated intestinal fluid is 96.59% for the mixed strain, and the lowest survival rate is 34.92% for Lactobacillus acidophilus. The results of this experiment show that Lactobacillus acidophilus is greatly affected by high intestinal pH and bile salts, but the mixed strain after the two strains are compounded has a synergistic effect, which can improve the strain's tolerance to the intestinal environment.

[0058] Table 1. Results of simulated gastrointestinal digestion

[0059]

[0060] 2. Analysis of antagonism between strains

[0061] 2.1 Analysis Method

[0062] Add OD 600 =0.8-1.0 The bacterial solution in the logarithmic growth phase is evenly applied. The sterile filter paper is evenly placed on the culture medium, and 20 μL of another bacterial solution is added to the filter paper, and cultured at 37°C for 24 hours. The appearance of the inhibition zone is observed. If there is an inhibition zone, it is recorded as "+", indicating that there is antagonism between the two strains; if there is no inhibition zone, it is recorded as "-", indicating that there is no antagonism between the two strains.

[0063] 2.2 Analysis Results

[0064] The antagonistic effects of Lactobacillus acidophilus and Lactobacillus plantarum are shown in Table 2. Due to the different sources, types and characteristics of the strains, the extracellular secretions produced by the strains may have a certain inhibitory effect and thus manifest as an antagonistic effect between the strains. The results of this experiment showed that there was no antagonistic effect between the two strains, which can provide a basis for subsequent strain compounding.

[0065] Table 2. Analysis of antagonism between strains

[0066] Group Lactobacillus acidophilus Lactobacillus plantarum Lactobacillus acidophilus / - Lactobacillus plantarum - /

[0067] 3. Analysis of the adhesion ability of probiotics

[0068] 3.1 Analysis Method

[0069] Caco-2 cells were inoculated in DMEM medium containing 10% FBS and cultured at 37°C with 5% CO2 for adherence. When they grew to about 80%, they were digested and counted. Then a certain number of cells were inoculated in a 12-well plate containing a slide. After the cells adhered, the medium was discarded and the cells were washed 2-3 times with PBS. 1 mL of probiotic suspension was added to each well and incubated in a 37°C incubator for 2 hours. The bacterial suspension was aspirated and the cells were washed 3 times with PBS (to remove non-adherent probiotics). Then, they were fixed with 4% paraformaldehyde solution for 25 minutes, washed twice with PBS, and then Gram-stained. Then, the cell slide was carefully removed with tweezers, left to dry naturally at room temperature, and the adhesion of probiotics to Caco-2 cells was observed under a microscope.

[0070] 3.2 Analysis Results

[0071] The adhesion of probiotics to human intestinal epithelial cells can prevent the colonization of pathogenic microorganisms on intestinal epithelial cells through competitive binding. According to the data in Table 3, compared with a single strain, the adhesion ability of mixed strains to Caco-2 cells is significantly enhanced.

[0072] Table 3. Analysis of adhesion ability of probiotics

[0073]

[0074] 4. In vitro hypoglycemic ability analysis

[0075] 4.1 Analysis Method

[0076] (1) α-glucosidase inhibition test

[0077] Add 50 μL of α-glucosidase solution (1.5 U / mL) to the fermentation supernatant or strain fragments, mix well and incubate at 37°C for 5 min, then add 75 μL PNPG (20 mmol / L) and mix well, continue incubation at 37°C for 15 min, and finally add 400 μL Na2CO3 (0.2 mol / L) to terminate the reaction. Measure the OD value at a wavelength of 405 nm in an ELISA reader and calculate the inhibition rate. Each sample was tested at least 3 times in parallel.

[0078] (2) Determination of α-amylase inhibitory activity

[0079] Mix 200 μL of fermentation supernatant or strain fragments with 200 μL of 1% soluble starch solution and incubate at 3°C ​​for 10 min, then add 200 μL of α-amylase working solution and continue incubation for 10 min. Then add 400 μL of DNS and boil in a boiling water bath for 5 min. After taking out, cool in cold water, add 4 mL of deionized water, vortex mix, and measure the OD value at 540 nm in a microplate reader.

[0080] 4.2 Analysis Results

[0081] Carbohydrates in food are mainly absorbed in the intestine in the form of monosaccharides. The starch and other polysaccharides ingested by the human body are degraded into oligosaccharides and disaccharides under the action of α-amylase in saliva, and then need to be further decomposed into glucose by α-glucosidase in the intestinal mucosa before they can be absorbed. Therefore, inhibitors of α-glucosidase and α-amylase can effectively lower blood sugar levels. This study explored the enzyme inhibition activity of the selected strains, and used the inhibition rate as an indicator to evaluate their in vitro hypoglycemic effect. Acarbose (antidiabetic drug) was used as a positive control in the experiment. The results are shown in Table 4. The α-glucosidase inhibition activity experiment showed that the fermentation supernatant of Lactobacillus plantarum, Lactobacillus acidophilus and their mixed bacteria had a certain inhibitory effect on α-glucosidase. When the supernatant was diluted 8 times, the inhibitory effect of the mixed strain on α-glucosidase reached 82.18%, which was significantly higher than other strains. However, the fermentation supernatant of Lactobacillus acidophilus did not show obvious inhibition when diluted 8 times, and its inhibition effect was 88.27% after reducing the dilution multiple. In the α-amylase inhibition experiment, the inhibitory activity of the mixed strain was 98.17% (p<0.05), which was significantly higher than that of a single strain; while the difference in inhibitory ability between Lactobacillus acidophilus (86.24%) and Lactobacillus plantarum (84.71%) was not significant. These results show that the in vitro enzyme inhibition activity of the strains can be improved after the strains are compounded, and there may be a certain synergistic effect. It is worth noting that the strain fragments of Lactobacillus plantarum, Lactobacillus acidophilus and their mixed strains did not show inhibitory activity against these two enzymes, indicating that their inhibitory ability mainly comes from the extracellular secretions of the strains, such as short-chain fatty acids or exopolysaccharides.

[0082] Table 4. In vitro hypoglycemic activity analysis

[0083]

[0084] 5. In vitro cholesterol-lowering ability analysis

[0085] 5.1 Analysis Method

[0086] The test bacterial solution was inoculated into MRS-cholesterol liquid medium so that the initial colony count was 10 8 CFU / mL, anaerobic culture at 37℃ for 24h, centrifugation at 8000r / min for 10min, and collection of supernatant. Cholesterol content in supernatant was determined by o-phthalaldehyde method.

[0087] 5.2 Analysis Results

[0088] According to the results in Table 5, the cholesterol clearance rates of the selected strains ranged from 29.72% to 36.10%, indicating that all three bacterial powders have a certain ability to lower cholesterol. Among them, the mixed strain had the best effect, with a clearance rate of 41.27%, which was significantly higher than that of Lactobacillus plantarum and Lactobacillus acidophilus (p<0.05), indicating that there may be a certain synergistic effect between the mixed strains. Studies have shown that probiotics hydrolyze bile salts through bile salt hydrolases, preventing bile salts from forming micelles with cholesterol and phospholipids, thereby inhibiting the absorption of cholesterol in the intestine; or binding to the cell membrane of probiotics, thereby achieving the effect of lowering cholesterol.

[0089] Table 5. In vitro cholesterol removal effect of probiotics

[0090]

[0091] Example 2 Screening of prebiotic types and ratios

[0092] 1. Analysis of probiotic preference

[0093] 1.1 Analysis Method

[0094] The test bacterial liquid was inoculated with 2% inoculum into MRS medium with different prebiotics (added at 1%) as the sole carbon source, cultured at 37°C with shaking, and the absorbance value (OD) at 600nm of the fermentation liquid was measured at 0, 6, 12, 24, 36, and 48h. 600 ), MRS medium without carbon source was used as negative control, MRS medium with glucose as carbon source was used as positive control, and MRS medium without bacterial solution was used as blank control.

[0095] 1.2 Analysis Results

[0096] This experiment screened out carbon sources suitable for the growth of probiotics by exploring the growth ability of strains in culture media with different prebiotics as the only carbon source. Figure 1-3 As shown, the three kinds of bacterial powder grow better in oligofructose, yeast spore β-glucan and stachyose. The three kinds of bacterial powder hardly grow in the culture medium with oligoxylose as the carbon source. The specific growth conditions are as follows: for the mixed strain, the three prebiotics with better performance are stachyose, yeast spore β-glucan, and oligofructose; for Lactobacillus acidophilus, the prebiotics with better performance are oligofructose, yeast spore β-glucan, and stachyose; for Lactobacillus plantarum, the prebiotics with better performance are yeast spore β-glucan, oligofructose, and stachyose. In summary, this experiment screened out three better prebiotics, namely stachyose, yeast spore β-glucan, and oligofructose, for subsequent compounding exploration.

[0097] 2. Analysis of prebiotic utilization

[0098] Ultra-high performance liquid chromatography was used to quantify the content of prebiotics in the culture medium before and after fermentation, and to analyze the utilization rate of different prebiotics by probiotics. Figure 4 The utilization rate of stachyose and yeast spore β-glucan by the mixed strain was significantly higher than that of the single strain (p<0.05). This result showed that the combination of Lactobacillus acidophilus and Lactobacillus plantarum enhanced the ability to utilize prebiotics.

[0099] 3. Screening of the preference of mixed strains by prebiotic ratio

[0100] According to the results of prebiotic preference analysis, the optimal prebiotics stachyose, oligofructose and yeast spore β-glucan of the mixed strain were selected for compounding exploration. This experiment designed 5 ratios for compounding exploration. The mass ratios of stachyose, oligofructose and yeast spore β-glucan were 1:1:1, 2:1:3, 2:3:1, 3:1:2 and 3:2:1, respectively.

[0101] 3.1 Analysis Method

[0102] Stachyose, oligofructose and yeast spore β-glucan were compounded at a mass ratio of 1:1:1, 2:1:3, 2:3:1, 3:1:2 and 3:2:1, respectively. The test bacterial solution was inoculated with 2% of the inoculum into MRS medium with different proportions of prebiotic combinations (added at 1%) as the sole carbon source, and cultured at 37°C with shaking. The absorbance value (OD) at 600nm of the fermentation liquid was measured at 0, 6, 12, 24, 36 and 48h. 600 ), MRS medium without carbon source was used as negative control, and MRS medium with glucose as carbon source was used as positive control.

[0103] 3.2 Analysis Results

[0104] The analysis results are shown in Figure 5 ,Depend on Figure 5 It can be seen that, considering the growth conditions in the early and late stages of proliferation, the proliferation ability of the mixed strain is best when the mass ratio of prebiotics is 3:2:1.

[0105] 4. Colonic fermentation analysis of prebiotic combinations with different ratios

[0106] 4.1. In vitro simulated colon fermentation experiment

[0107] (1) Preparation of fecal fermentation liquid: fresh feces were collected, added with sterile PBS buffer at pH 7.0 at a dilution ratio of 1:9 (w / v), homogenized for 10 min, and the fecal mixture was centrifuged at 1000 rpm for 10 min to remove impurities. The upper turbid liquid was retained as fecal fermentation liquid for later use.

[0108] (2) In vitro simulated colon fermentation experiment: 2 mL of mixed fecal suspension was added to 8.0 mL of basal nutrient medium containing 200 mg of intervention material, and the mixture was cultured at 37 °C under anaerobic conditions for 24 h. Samples were collected at 24 h and centrifuged at 12,000 rpm for 10 min to collect the bacterial precipitate. DNA was extracted according to the instructions of the fecal genomic DNA extraction kit, and the extracted DNA was diluted to 1 ng / μL. The standard curve was prepared with the corresponding bacterial plasmid standard that was successfully sequenced, and qPCR detection was performed. Under the same conditions, the culture without intervention material was the control group, the culture with inulin added was the positive control group, and the culture with different proportions of prebiotic combinations was the experimental group.

[0109] 4.2 Analysis Results

[0110] The experimental results are as follows Figure 6 As shown, in terms of Lactobacillus regulation, the effect of the intervention group was significantly higher than that of the control group. When the ratio of compound prebiotics was 2:3:1 and 3:2:1, there was no significant difference compared with the positive control inulin group. Compared with other groups, the abundance of Lactobacillus was significantly increased. In terms of Bifidobacterium regulation, the effect of the compound prebiotic intervention group was significantly higher than that of the control group, and the abundance of Bifidobacterium could be significantly increased when the ratio was 2:3:1 and 3:2:1. In terms of Akkermansia regulation, compared with other groups, the compound prebiotics with a compound ratio of 3:2:1 could significantly increase the abundance of Akkermansia. In summary, when the ratio of compound prebiotics is 3:2:1, it can significantly promote the increase in the abundance of beneficial bacteria in the human intestinal flora.

[0111] Example 3 Effect of the optimal prebiotic ratio (3:2:1) on probiotic proliferation and acid production

[0112] The growth and acid production of Lactobacillus plantarum, Lactobacillus acidophilus and mixed strains were analyzed using a compound prebiotic consisting of stachyose, oligofructose and yeast spore β-glucan in the optimal ratio of 3:2:1 as the carbon source.

[0113] 1. Effect of the optimal prebiotic ratio (3:2:1) on probiotic proliferation and acid production

[0114] 1.1 Analysis Method

[0115] The test bacterial liquid was inoculated with 2% inoculum into MRS medium with the optimal prebiotic combination (added at 1%) as the sole carbon source, cultured at 37°C with shaking, and the absorbance value (OD) at 600 nm of the fermentation liquid was measured at 0, 6, 12, 24, 36, and 48 h. 600 ) and pH.

[0116] 1.2 Analysis Results

[0117] The results are as follows Figure 7As shown. It can be seen that the three kinds of bacterial powder can proliferate and produce acid well in the compound prebiotics. After the fermentation, OD 600 The change is around 1.0. Among them, the growth conditions of Lactobacillus acidophilus and the mixed strains in the lag phase and logarithmic growth phase are similar, but the growth of Lactobacillus acidophilus in the later stage of fermentation is slightly better than that of the mixed strains. The pH drop of the three strains in the compound prebiotics is similar to their growth conditions, but the pH drop of the mixed strains in the later stage of fermentation is better than that of Lactobacillus acidophilus. Probiotics can decompose prebiotics by hydrolyzing key glycosidic bonds and then proliferate and produce acid. The types and activities of related enzymes are different among different strains, resulting in differences in their proliferation and acid production in the same carbon source.

[0118] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A synbiotic composition, characterized in that: The synbiotic composition includes probiotics and prebiotics; The probiotics are selected from at least one of Lactobacillus acidophilus NCFM and Lactobacillus plantarum 6595; The prebiotic is selected from at least one of stachyose, oligofructose and yeast spore β-glucan.

2. The synbiotic composition according to claim 1, characterized in that The probiotics are Lactobacillus acidophilus NCFM and Lactobacillus plantarum 6595.

3. The synbiotic composition according to claim 2, characterized in that The mass ratio of the Lactobacillus acidophilus NCFM to the Lactobacillus plantarum 6595 is 1:0.1-1.

4. The synbiotic composition according to claim 1, characterized in that The prebiotics are stachyose, oligofructose and yeast spore beta-glucan.

5. The synbiotic composition according to claim 4, characterized in that The mass ratio of stachyose, oligofructose and yeast spore beta-glucan is 1-3:1-3:1-3.

6. The synbiotic composition according to claim 5, characterized in that The mass ratio of stachyose, oligofructose and water-soluble beta-glucan is 2-3:2-3:

1.

7. The synbiotic composition according to claim 6, characterized in that The mass ratio of stachyose, oligofructose and water-soluble beta-glucan is 3:2:

1.

8. The synbiotic composition according to claim 1, characterized in that The mass ratio of the prebiotics to the probiotics is 1:0.1-1.

9. Use of the synbiotic composition according to any one of claims 1 to 8 in the preparation of food, dietary supplement or medicine.

10. The use according to claim 9, characterized in that The food, dietary supplement or medicament is used to treat one or more of the following diseases and conditions in a mammal: (1) Regulate intestinal flora; (2) Improve blood sugar and blood lipid abnormalities; (3) improving obesity, reducing body fat mass, and / or reducing mesenteric fat mass; (4) Improve type 2 diabetes; (5) Improve insulin resistance.

Images